Stay updated on Re-sensitizing Carboplatin-Resistant Ovarian Cancer: FAK Clinical Trial
Sign up to get notified when there's something new on the Re-sensitizing Carboplatin-Resistant Ovarian Cancer: FAK Clinical Trial page.

Latest updates to the Re-sensitizing Carboplatin-Resistant Ovarian Cancer: FAK Clinical Trial page
- Check3 days agoChange DetectedThe study record page now shows a 403 Forbidden error, replacing the detailed study content with a generic error page. This indicates that access to the core trial information is blocked.SummaryDifference20%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision metadata on the page updated from v3.6.5 to v3.6.6, indicating a newer version of the study details page. This appears to be a maintenance update rather than a change to study data or content.SummaryDifference0.1%

- Check45 days agoChange DetectedThe page now shows Revision: v3.6.5, indicating an update to the revision history, and a large block of older content items from the previous revision appears to have been removed.SummaryDifference19%

- Check53 days agoChange DetectedThe ROCKIF trial record shows termination due to funding loss and cessation of enrollment, with results posted. The entry also documents changes to dosing arms and schedules while some contact information sections were removed.SummaryDifference5%

- Check60 days agoChange DetectedThe page revision label was updated from v3.6.3 to v3.6.4, indicating a backend/template update to the Study Details page. The change does not modify the study information or user-facing content.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page's revision label was updated to v3.6.3, replacing the previous v3.6.2, indicating a minor internal version increment.SummaryDifference0.1%

Stay in the know with updates to Re-sensitizing Carboplatin-Resistant Ovarian Cancer: FAK Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Re-sensitizing Carboplatin-Resistant Ovarian Cancer: FAK Clinical Trial page.